429 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
25470070	81	Probing the carboxyester side chain in controlled deactivation (-)-d(8)-tetrahydrocannabinols.	Northeastern University
28088085	42	New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.	University of Sassari
27560280	138	Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor.	Pontificia Universidad Cat£Lica De Chile
27448919	69	Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality.	German University In Cairo
27671499	46	Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.	Janssen Research and Development
27671496	46	Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.	Janssen Research and Development
27240274	37	A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives.	Neuroscienze Pharmaness S.C.A R.L.
27078864	46	Synthesis and pharmacological evaluation of new biphenylic derivatives as CB2 receptor ligands.	Universit£
26888301	34	Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain.	University of Siena
26789378	57	Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology.	Instituto De Qu£Mica M£Dica
26756097	56	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility.	Universit£
26890113	41	Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.	Universit£
26922225	91	Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists.	Universit£
26827137	26	Pyrazole antagonists of the CB1 receptor with reduced brain penetration.	Rti International
26209834	46	Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists.	Universit£
26275680	68	Synthesis and biological evaluation of (3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist.	University of Tennessee Health Science Center
26149623	7	Combining Mass Spectrometric Metabolic Profiling with Genomic Analysis: A Powerful Approach for Discovering Natural Products from Cyanobacteria.	University of California Berkeley
26203658	39	Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors.	University of Auckland
26151231	154	Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.	Zhejiang University
26000707	20	Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.	The University of Mississippi
25950914	84	Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor.	Institute of Pharmaceutical Sciences
25466197	32	Novel azoles as potent and selective cannabinoid CB2 receptor agonists.	Ipsen Innovation
25935384	26	New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.	University of Pisa
25699149	52	Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis.	University of Lille
25760146	49	3'-functionalized adamantyl cannabinoid receptor probes.	University of Hawaii At Manoa
25671648	6	Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer.	Instituto De Qu£Mica M£Dica
25644673	186	Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.	Zhejiang University
25599952	20	Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor.	Institute of Pharmaceutical Sciences
25703248	3	Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.	University of Massachusetts Medical School
25556098	36	Selective CB2 receptor agonists. Part 1: the identification of novel ligands through computer-aided drug design (CADD) approaches.	Boehringer Ingelheim Pharmaceuticals
25701254	48	Novel tail and head group prostamide probes.	Northeastern University
25486424	30	Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands.	Universit£
25096297	63	Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure.	Julius-Maximilians-Universit£T W£Rzburg
25072877	40	One-pot heterogeneous synthesis of¿(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.	University of Perugia
25065940	77	Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.	Universit£
24984935	24	Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB2R selective benzimidazoles reveal unexpected intrinsic properties.	Julius-Maximilians-Universit£T W£Rzburg
24972328	26	Identification of endocannabinoid system-modulating N-alkylamides from Heliopsis helianthoides var. scabra and Lepidium meyenii.	University of Szeged
24863744	15	DDD-028: a potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain.	University of Missouri
24856059	7	trans-Caryophyllene is a natural agonistic ligand for peroxisome proliferator-activated receptor-a.	Korea University
25575658	83	Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.	Boehringer Ingelheim Pharmaceuticals
25556092	85	Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.	Boehringer Ingelheim Pharma
25499880	51	Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome.	Raqualia Pharma
25488844	154	Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.	Arena Pharmaceuticals
25487422	93	Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.	University of Oxford
25466177	24	The SAR development of substituted purine derivatives as selective CB2 agonists for the treatment of chronic pain.	Eli Lilly
25272206	88	CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.	Universit£
25162172	51	Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).	Research Triangle Institute
24922543	24	Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands.	Universit£
24856183	4	Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity.	Corbus Pharmaceuticals
24900848	11	C-ring cannabinoid lactones: a novel cannabinergic chemotype.	Northeastern University
23865723	169	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.	Arena Pharmaceuticals
24461289	46	Benzimidazole CB2 agonists: design, synthesis and SAR.	Merck Research Laboratories
23621789	69	Novel adamantyl cannabinoids as CB1 receptor probes.	Northeastern University
23466226	26	Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors.	University of Arkansas For Medical Sciences
23434135	27	Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21.	Instituto De Qu£Mica M£Dica
23395112	32	Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists.	Shionogi
23380378	127	Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening.	F. Hoffmann-La Roche
24729834	79	Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CB	University of Pittsburgh
24900561	25	Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.	University of Bonn
23406429	83	Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.	University of Pittsburgh
23350768	196	Design, synthesis, and pharmacological properties of new heteroarylpyridine/heteroarylpyrimidine derivatives as CB(2) cannabinoid receptor partial agonists.	Universit£
23227781	119	Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.	Astrazeneca
16539390	14	Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.	University of Kuopio
22548457	60	Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists.	Universit£
21923175	29	Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists.	Merck Research Laboratories
21334892	39	Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.	Msd
21316962	31	Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.	Merck Research Laboratories
20634067	23	Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists.	Schering-Plough Research Institute
20005703	66	Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB(2) agonists for the treatment of inflammatory pain.	Glaxosmithkline
19864133	42	2-Amino-5-aryl-pyridines as selective CB2 agonists: synthesis and investigation of structure-activity relationships.	Glaxosmithkline
19477133	13	Synthesis of quinolinyl and isoquinolinyl phenyl ketones as novel agonists for the cannabinoid CB2 receptor.	Helsinki University of Technology
19249138	142	Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.	Universidade Federal Do Rio De Janeiro
23147076	163	Structure-activity relationships of 2-arylamido-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide derivatives as cannabinoid receptor agonists and their analgesic action.	Nycomed Pharma
22341572	61	Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.	Rti International
23098108	36	Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists.	Research Triangle Institute
23072339	132	Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.	University of Pittsburgh
22916707	76	7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.	University of Bonn
23017078	62	4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis.	University of Lille
22738638	59	Assay and inhibition of diacylglycerol lipase activity.	Northeastern University
22738271	250	7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.	Universit£
23164658	78	2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents.	University of Bologna
23151320	37	Scaffold hopping strategy toward original pyrazolines as selective CB2 receptor ligands.	Avenue De L'Universit£
23085772	82	Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.	Universit£
22959249	79	JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities.	Jenrin Discovery
22571451	46	Indole-2-carboxamides as allosteric modulators of the cannabinoid CB1 receptor.	Sapienza University of Rome
22796181	51	C3-heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor.	University of Hawaii At Manoa
24900484	64	Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.	TBA
22765893	32	Discovery and optimization of novel purines as potent and selective CB2 agonists.	Eli Lilly
22607668	66	N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration.	Astrazeneca
22372835	71	Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.	Research Triangle Institute
22421019	62	Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent.	Shionogi
22483967	38	Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.	Universit£
22444677	45	Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent.	Shionogi
22437111	34	CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: reduction of CNS side effects by introducing polar functional groups.	Shionogi
22421020	9	Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.	Merck Research Laboratories
22370265	63	Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB2 receptor agonists for pain management.	Abbott Laboratories
21428406	70	N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors.	National Institute of Mental Health
20943404	24	1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-¿(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor.	Clemson University
20554448	1	Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2).	Johns Hopkins Medical Institutions
20718492	74	Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands.	Universit£
20363132	34	Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern.	Solvay Pharma
20137935	46	Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.	Solvay Pharma
20031412	36	Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.	Solvay Pharma
20018510	73	Diaryl piperidines as CB1 receptor antagonists.	Merck Research Laboratories
19595596	114	Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile.	Sapienza University of Rome
19520572	55	Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.	Vernalis (R&D)
19435366	34	Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists.	Universita Di Pisa
19278853	67	Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.	University of Bonn
19143566	52	Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.	University of Innsbruck
19115816	38	6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.	The University of Texas M.D. Anderson Cancer Center
18680277	198	Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.	Amgen
18680276	46	Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo.	Universit£
18666769	32	Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.	The University of Texas M.D. Anderson Cancer Center
18579386	40	Novel sterically hindered cannabinoid CB1 receptor ligands.	University of Salerno
18448340	27	Aminopyrazine CB1 receptor inverse agonists.	Neurogen
18440813	55	The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives.	Pfizer
18430570	76	Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.	Adolor
18424134	114	New tetrazole-based selective anandamide uptake inhibitors.	Sapienza University of Rome
18394887	37	5-Sulfonyl-benzimidazoles as selective CB2 agonists.	Johnson & Johnson Pharmaceutical Research & Development
17919913	55	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.	Clemson University
18006322	43	Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.	Taisho Pharmaceutical
18337096	37	Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists.	Reen Cross
17483457	58	A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.	Abbott Laboratories
17942307	34	New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.	Universit£
17884496	51	N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.	Taisho Pharmaceutical
17630726	32	Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.	Novartis Institutes For Biomedical Research
17561406	67	Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors.	Universit£
16279794	46	Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.	Universit£
17181138	27	Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.	Merck Research Laboratories
16392793	42	Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.	Universit£
16213718	93	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies.	Institute of Biomolecular Chemistry
16140010	32	Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.	Solvay Pharma
15771428	66	Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.	Solvay Pharma
16078824	48	The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.	Universit£
12672252	104	Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.	Universidad Complutense
12747783	17	Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties.	Bristol-Myers Squibb
11741470	40	Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.	Universidad Complutense
9857088	16	The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes.	Kennesaw State University
22284817	82	¿-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.	Astrazeneca R&D Montreal
22209458	114	Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.	Vernalis (R&D)
22130134	58	5-sulfonyl-benzimidazoles as selective CB2 agonists-part 2.	Janssen Pharmaceutica
22172309	12	Novel bioactive metabolites of dipyrone (metamizol).	Philipps-Universit£T
21999614	11	Cannabinomimetic lipid from a marine cyanobacterium.	University of California
22044209	56	Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.	Universit£
21996466	40	1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands.	Sapienza University of Rome
21962575	8	Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies.	Bristol-Myers Squibb
21937154	9	Asymmetric synthesis and biological evaluation of N-cyclohexyl-4-[1-(2,4-dichlorophenyl)-1-(p-tolyl)methyl]piperazine-1-carboxamide as hCB1 receptor antagonists.	Shanghai Institute of Materia Medica
21880487	21	Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.	Northeastern University
21875798	30	Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity.	Rti International
21855337	3	Design and evaluation of a novel fluorescent CB2 ligand as probe for receptor visualization in immune cells.	University of Montana
21835510	14	Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the agonist binding site of the human CB2 receptor.	Universit£
21902175	24	Bioactive prenylogous cannabinoid from fiber hemp (Cannabis sativa).	Universita` Del Piemonte Orientale
21872477	43	Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives.	The University of Texas
21741835	41	Structure-activity relationship studies of novel pyrazole and imidazole carboxamides as cannabinoid-1 (CB1) antagonists.	Dr. Reddy'S Laboratories
21702498	34	Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.	Universita Degli Studi Di Siena
21667972	5	Benzyl derivatives with in vitro binding affinity for human opioid and cannabinoid receptors from the fungus Eurotium repens.	The University of Mississippi
21737287	3	Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging.	Imir K.U. Leuven
21689933	24	Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters.	Boehringer Ingelheim Pharmaceuticals
21675776	22	Development of endocannabinoid-based chemical probes for the study of cannabinoid receptors.	Universidad Complutense De Madrid
21669533	26	Optimisation of a novel series of selective CNS penetrant CB(2) agonists.	Pfizer
20971001	45	Indazole derivatives as novel bradykinin B1 receptor antagonists.	Merck Research Laboratories
21493064	69	Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.	Merck
21420857	115	Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.	Merck Research Laboratories
21354795	95	1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.	Boehringer Ingelheim Pharmaceuticals
21420860	34	Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.	Merck Research Laboratories
21183257	202	Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.	Universit£
20979417	83	4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.	Universite£? Lille-Nord De France
21115245	69	Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain.	Merck Research Laboratory
20943290	54	Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.	Sapienza University of Rome
21074998	80	Synthesis, binding studies and molecular modeling of novel cannabinoid receptor ligands.	German University In Cairo
20850969	33	Expansion of SAR studies on triaryl bis sulfone cannabinoid CB2 receptor ligands.	Merck Research Laboratories
20845959	94	Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.	Research Triangle Institute
20925434	43	Novel 1',1'-chain substituted hexahydrocannabinols: 9ß-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist.	Northeastern University
20688519	58	Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists.	Abbott Healthcare Products
20673729	60	Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.	Green Cross
20621488	13	Synthesis and pharmacology of 1-methoxy analogs of CP-47,497.	Clemson University
20593789	47	Heteroadamantyl cannabinoids.	University of Hawaii At Manoa
20483606	71	Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation.	Merck Research Laboratories
20218623	68	Emerging targets in osteoporosis disease modification.	Amgen
20423086	93	Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.	Merck Research Laboratories
20096577	42	Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.	Merck Research Laboratories
20137936	7	Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor.	National Institute of Radiological Sciences
20047779	86	Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach.	Chinese Academy of Sciences
19767206	9	Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors.	National Institute of Mental Health
20045337	117	Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.	Green Cross
20022504	9	Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase.	University of Salerno
20189815	20	Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging.	Indiana University School of Medicine
20079638	61	Synthesis and structure-activity relationship of substitutions at the C-1 position of Delta9-tetrahydrocannabinol.	Amri
20005710	70	Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.	Merck Research Laboratories
19919895	54	Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.	Adolor
20047331	30	Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.	Solvay Pharma
19921781	220	Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.	Abbott Laboratories
19850473	30	Pentacycle derivatives as cannabinoid CB1 receptor ligands.	Green Cross
19743867	51	Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.	Glaxosmithkline
19736007	31	Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.	Adolor
19646869	54	Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.	Adolor
19632830	47	Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.	Merck Research Laboratories
19699640	12	Synthesis and SAR of 1,4,5,6-tetrahydropyridazines as potent cannabinoid CB1 receptor antagonists.	Solvay Pharma
19596576	60	Substituted pyrimidines as cannabinoid CB1 receptor ligands.	Green Cross
19500981	26	Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis.	Pfizer
19515560	24	Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.	Vernalis (R&D)
19161308	4	Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.	University of Montpellier
	33	Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors	TBA
	38	New class of potent ligands for the human peripheral cannabinoid receptor	TBA
19530697	59	Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.	National Health Research Institutes
19331413	54	New resorcinol-anandamide"hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo.	Universita Degli Studi Di Siena
19328684	67	Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation.	Merck Research Laboratories
19328683	22	Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect.	Zydus Research Centre
19320488	171	1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.	Merck Research Laboratories
19269817	28	Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.	Green Cross
19250829	46	Quantitative structure-activity relationship (QSAR) for a series of novel cannabinoid derivatives using descriptors derived from semi-empirical quantum-chemical calculations.	St. Jude Children'S Research Hospital
19243942	30	Morpholine containing CB2 selective agonists.	Boehringer Ingelheim Pharmaceuticals
19230659	12	Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.	University of Tennessee-Memphis
19128970	18	Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice.	University of California
19095444	48	1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.	National Central University
19091565	101	CB2 selective sulfamoyl benzamides: optimization of the amide functionality.	Adolor
19062274	72	Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.	Amgen
19053765	15	New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide.	Martin-Luther-Universitaet
19022666	71	Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists.	Green Cross
18977140	43	2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 3: Synthesis and activity of isosteric analogs.	Shionogi
18954042	117	Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.	Green Cross
18831576	66	Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.	Sapienza University of Rome
18754613	23	Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors.	National Institute of Mental Health
18712856	129	Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists.	National Health Research Institutes
18640038	74	Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.	Amgen
18595717	2	Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptors.	The National Hellenic Research Foundation
18524604	36	Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs.	University of Tennessee-Memphis
18522867	149	Novel benzimidazole derivatives as selective CB2 agonists.	Astrazeneca R&D MontréAl
18512901	27	Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations.	Research Triangle Institute
18342403	13	Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant.	Università
18243711	76	Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.	Central Research Institute
17582659	22	Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor.	Monash University (Parkville Campus)
18255291	45	Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.	Evotec (Uk)
17979261	8	Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model.	Zydus Research Centre
17915849	53	Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.	Université
17884494	79	New 1,2,3,4-tetrahydropyrrolo[3,4-b]indole derivatives as selective CB2 receptor agonists.	Astrazeneca R&D Montreal
17827022	16	Novel, potent THC/anandamide (hybrid) analogs.	Organix
17643986	11	Sulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists.	Taisho Pharmaceutical
17608398	14	Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.	TBA
17604171	20	Metabolically labile cannabinoid esters: a 'soft drug' approach for the development of cannabinoid-based therapeutic drugs.	Università
17574850	27	Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring.	Schering-Plough Research Institute
17531479	65	2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds.	Shionogi
17521907	50	2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: discovery of CB2 receptor selective compounds.	Shionogi
17521177	90	The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.	The National Hellenic Research Foundation
17507224	82	Biaryl cannabinoid mimetics--synthesis and structure-activity relationship.	Adolor
17497806	1	Self-assembling cannabinomimetics: supramolecular structures of N-alkyl amides.	Department of Chemistry and Applied Biosciences
17477516	115	Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.	Glaxosmithkline
17383180	52	Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity.	Bayer Healthcare
17293109	69	Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists.	Merck Research Laboratories
17270441	72	Lead optimization of 5,6-diarylpyridines as CB1 receptor inverse agonists.	Merck Research Laboratories
17110113	2	Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.	Teikyo University
17107792	38	Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.	Bayer Healthcare
16889960	56	1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors.	Clemson University
16682198	4	Synthesis of a potential photoactivatable anandamide analog.	University of Montpellier
16570929	29	Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.	University of Piemonte Orientale
16392798	46	Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.	Columbia University College of Physicians and Surgeons
16263284	36	Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists.	Merck Research Laboratories
16263283	55	New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.	Pfizer
16115769	39	Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies.	Schering-Plough Research Institute
16005223	64	1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.	Clemson University
15993070	4	Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor.	University of Nottingham
15664857	24	Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies.	Schering-Plough Research Institute
15664830	64	Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists.	Merck Research Laboratories
14736243	49	Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.	Solvay Pharma
14505654	14	Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids.	University of Tennessee-Memphis
12161142	34	C-3 Amido-indole cannabinoid receptor modulators.	Bristol-Myers Squibb
12061874	60	Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716).	Research Triangle Institute
32527545	27	The discovery of azetidine-piperazine di-amides as potent, selective and reversible monoacylglycerol lipase (MAGL) inhibitors.	Janssen Research & Development
32340793	64	Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity.	Universit£
32787142	88	Exploration of Alternative Scaffolds for P2Y	National Institute of Diabetes and Digestive and Kidney Diseases
32515588	53	Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-	University of Siena
32429662	39	Discovery of Aryl Formyl Piperidine Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase Inhibitors.	China Pharmaceutical University
11020293	42	Novel cannabinol probes for CB1 and CB2 cannabinoid receptors.	Organix
30583970	49	Benzo[d]thiazol-2(3H)-ones as new potent selective CB	Univ. Lille
27482723	73	Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.	Research Triangle Institute
27624523	33	Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as CB	Universit£
27367336	78	Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues.	Northeastern University
27309150	212	Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.	Instituto De Qu£Mica M£Dica
30816712	78	Plant-Based Modulators of Endocannabinoid Signaling.	Concordia University Wisconsin
30715876	58	Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.	University of Pisa
31596583	306	Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators.	Research Triangle Institute
30096653	10	Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus.	Univerisity of Eastern Finland (Uef)
31301950	71	Functionalized 6-(piperidin-1-yl)-8,9-diphenyl purines as inverse agonists of the CB1 receptor - SAR efforts towards selectivity and peripheralization.	Rti International
31302448	197	Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties.	German University In Cairo
31185414	86	Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment.	Alma Mater Studiorum-University of Bologna
31185168	144	Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.	Rti International
31319265	62	Strategies to develop selective CB	The University of Sydney
31609608	59	Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo.	Julius Maximilian University of W£Rzburg
31913038	13	Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.	University of Florida
31891265	10	Isolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal	University of Modena and Reggio Emilia
30996802	52	Polycyclic Maleimide-based Scaffold as New Privileged Structure for Navigating the Cannabinoid System Opportunities.	University of Bologna
9379452	8	Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.	Kennesaw State University
9379442	61	Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.	Institute of Science
30359820	59	Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease.	Universit£
8831752	9	Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.	Clemson University
24602792	6	Benzimidazole: an emerging scaffold for analgesic and anti-inflammatory agents.	Asbasjsm College of Pharmacy
24445310	25	Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists.	Zhejiang University
24518874	61	1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor.	Universit£
24286207	30	Controlled-deactivation cannabinergic ligands.	Northeastern University
24291040	5	Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor.	Sanofi R&D
24139843	38	Development of fluorinated CB(2) receptor agonists for PET studies.	Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
23795771	94	Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.	Lilly Research Laboratories
24175626	17	Identification of CB1/CB2 ligands from Zanthoxylum bungeanum.	National Institute On Aging
24141201	8	Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity.	Instituto De Qu£Mica M£Dica
24125850	89	Mastering tricyclic ring systems for desirable functional cannabinoid activity.	The University of Montana
24041123	20	Peripherally selective diphenyl purine antagonist of the CB1 receptor.	Research Triangle Institute
23855811	14	The importance of hydrogen bonding and aromatic stacking to the affinity and efficacy of cannabinoid receptor CB2 antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide (SR144528).	University of Texas-Pan American
23849204	57	3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.	Universit£
23738526	2	An effective prodrug strategy to selectively enhance ocular exposure of a cannabinoid receptor (CB1/2) agonist.	Novartis Institutes For Biomedical Research
23623258	36	Selective CB2 agonists with anti-pruritic activity: discovery of potent and orally available bicyclic 2-pyridones.	Shionogi
23697626	167	Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists.	Universit£
23631463	14	Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.	The University of Kansas
30496988	25	Pharmaceutical and medicinal significance of sulfur (S	Wuhan University of Technology
21215643	20	Microwave-assisted synthesis of quinoline, isoquinoline, quinoxaline and quinazoline derivatives as CB2 receptor agonists.	University of Eastern Finland
16279774	2	Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.	University of Kuopio
10882356	40	A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.	Universit£
30144699	53	Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors.	University of Pisa
30339387	114	6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB	Janssen Research & Development
29407590	73	Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment.	University of Otago
29232588	56	Bioactive products from singlet oxygen photooxygenation of cannabinoids.	The University of Mississippi
30122284	70	Oximes short-acting CB1 receptor agonists.	Northeastern University
30077609	74	Synthesis and pharmacological characterization of functionalized 6-piperazin-1-yl-purines as cannabinoid receptor 1 (CB1) inverse agonists.	Rti International
29688015	67	Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor.	Rti International
30196704	90	( R)- N-(1-Methyl-2-hydroxyethyl)-13-( S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes.	Northeastern University
29229226	42	Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB	University of Sassari
29079014	25	Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor.	University of Pisa
30217464	18	Synthesis of oxidative metabolites of CRA13 and their analogs: Identification of CRA13 active metabolites and analogs thereof with selective CB	Kyung Hee University
29902723	199	Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18.	University of Bonn
29793210	91	Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system.	University of Bern
29360044	47	Development of novel oxazolo[5,4-d]pyrimidines as competitive CB	Univ. Lille
29856219	11	Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.	TBA
29259753	70	Discovery of APD371: Identification of a Highly Potent and Selective CB	Arena Pharmaceuticals
29240420	16	Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids.	University of Eastern Piedmont
28651225	70	Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.	Zhejiang University
28673732	31	Design, synthesis and biological evaluation of GPR55 agonists.	University of North Carolina At Greensboro
28284861	27	Biological evaluation of pyridone alkaloids on the endocannabinoid system.	University of Bern
28792219	61	Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution.	Research Triangle Institute
28726401	55	Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis.	East China Normal University
29309142	36	Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors.	University of Ferrara
28626532	80	Development of Quinazoline/Pyrimidine-2,4(1	Zhejiang University
28608697	20	Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies.	Universit£
29400965	83	Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles.	Julius Maximilian University of W£Rzburg
23808805	42	Carbonic anhydrase inhibitors. Phenols incorporating 2- or 3-pyridyl-ethenylcarbonyl and tertiary amine moieties strongly inhibit Saccharomyces cerevisiae ß-carbonic anhydrase.	Ataturk University
27588426	2	Inhibition of the Flavin-Dependent Monooxygenase Siderophore A (SidA) Blocks Siderophore Biosynthesis and Aspergillus fumigatus Growth.	Virginia Tech
27305312	4	Capture-Tag-Release: A Strategy for Small Molecule Labeling of Native Enzymes.	Fairfield University
27113261	12	2-Prenylated m-dimethoxybenzenes as potent inhibitors of 15-lipo-oxygenase: inhibitory mechanism and SAR studies.	Ferdowsi University of Mashhad
27376460	5	Synthesis, anti-inflammatory, analgesic, 5-lipoxygenase (5-LOX) inhibition activities, and molecular docking study of 7-substituted coumarin derivatives.	Nirma University
26808391	6	A Dual Non-ATP Analogue Inhibitor of Aurora Kinases A and B, Derived from Resorcinol with a Mixed Mode of Inhibition.	Jawaharlal Nehru Centre For Advanced Scientific Research
26833890	18	Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease.	Yogi Vemana University
26575582	15	Development of 2-(Substituted Benzylamino)-4-Methyl-1, 3-Thiazole-5-Carboxylic Acid Derivatives as Xanthine Oxidase Inhibitors and Free Radical Scavengers.	Jamia Hamdard
26469307	7	Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b.	University of Leipzig
24040835	14	The natural product dihydrotanshinone I provides a prototype for uncharged inhibitors that bind specifically to the acetylcholinesterase peripheral site with nanomolar affinity.	Mayo Clinic
9353393	5	Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.	Torrey Pines Institute For Molecular Studies
20827790	21	A novel competitive class of α-glucosidase inhibitors: (E)-1-phenyl-3-(4-styrylphenyl)urea derivatives.	Gyeongsang National University
8730737	23	Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety.	Smithkline Beecham Pharmaceuticals
8667026	14	The C-terminal domain of the mGluR1 metabotropic glutamate receptor affects sensitivity to agonists.	Cns Research
7716273	19	Properties of the VIP-PACAP type II receptor stably expressed in CHO cells.	UniversitÉ
19385613	60	Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties.	Novo Nordisk
17467988	21	Novel glucocorticoids containing a 6,5-bicyclic core fused to a pyrazole ring: synthesis, in vitro profile, molecular modeling studies, and in vivo experiments.	Merck Research Laboratories
17125251	20	A 2.13 A structure of E. coli dihydrofolate reductase bound to a novel competitive inhibitor reveals a new binding surface involving the M20 loop region.	University of Prince Edward Island
8894098	20	Discovery and optimization of nonpeptide HIV-1 protease inhibitors.	Parke-Davis Pharmaceutical Research
17393456	4	Identification of novel fragment compounds targeted against the pY pocket of v-Src SH2 by computational and NMR screening and thermodynamic evaluation.	University College London
8164260	23	The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors.	Merck Research Laboratories
2200122	1	Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.	Abbott Laboratories